Proteasomi-inhibiittorimarkkinat: nykyinen analyysi ja ennuste (2023-2030)

$3999 - $6999

Antotavan painottaminen (suun kautta, suonensisäisesti ja muut); Indikaatio (vaippasolulymfooma, multippeli myelooma ja muut); ja alue/maa

Sivuja:

154

Taulukko:

44

Kuvio:

104

Raportin tunnus:

UMHE212629

Maantiede:

Poista valinta
  Hanki näyte
Raportin kuvaus
Sisällysluettelo
Tutkimusmenetelmät

Raportin kuvaus

Proteasomi-inhibiittorimarkkinat
Proteasomi-inhibiittorimarkkinat

The proteasome inhibitor market was valued at USD 1.78 Billion in 2022 and is expected to grow at a CAGR of 8.01% during the forecast period (2023-2030). Proteasome inhibitors are a class of drugs used in cancer treatment, particularly for certain types of blood cancers like multiple myeloma and mantle cell lymphoma. These inhibitors interfere with the action of proteasomes, cellular structures responsible for breaking down proteins. By inhibiting proteasomes, these drugs disrupt the normal protein degradation process in cancer cells, leading to their accumulation and eventually triggering cell death. Proteasome inhibitors mainly gained prominence in the market due to the rising number of pancreatic cancer cases. Esimerkiksi according to the National Cancer Institute, the rate of new cases of pancreatic cancer was 13.3 per 100,000 men and women per year in the year 2020. In addition to this, investments in oncology departments as well as government awareness programs regarding pancreatic cancer have increased significantly in recent years, which are the key factors that are creating opportunities for the market.

AbbVie Inc.; Amgen Inc.; Johnson & Johnson Services, Inc.; Takeda Pharmaceutical Company Limited; TG Therapeutics; Pfizer Inc.; QLi5 Therapeutics GmbH; Baxter; GSK plc.; Kezar Life Sciences Inc. are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Raportissa esitetyt näkemykset

“Amongst mode of administration, intravenous category to witness higher CAGR during the forecast period”

Based on the mode of administration, the market is segmented into oral, intravenous, and others. The intravenous segment is expected to grow with a high CAGR during the forecast period because of its faster mode of action and effectiveness. For instance, according to the National Library of Medicine’s article in February 2023, the intravenous mode of drug administration provides the most complete drug availability with negligible delay. Also, this mode is comfortable for patients who face difficulty in ingesting medicines orally. Thus, the intravenous segment among modes of administration is expected to witness a higher CAGR during the forecast period.

“Amongst indication, held a significant share in the market in 2022”

Based on indication, the market is categorized into mantle cell lymphoma, multiple myeloma, and others. The multiple myeloma segment is dominating the market owing to the rising incidences of multiple myeloma. For instance, according to the American Cancer Society, in the U.S. the average lifetime risk of getting multiple myeloma is about 1 in 103 for men and about 1 in 131 for women. Multiple myeloma is a type of cancer that affects plasma cells, a type of white blood cell in the bone marrow. It often leads to the production of abnormal antibodies and can cause bone damage, anemia, and kidney problems. Thus, multiple myeloma held a significant share in the proteasome inhibitors market in 2022.

"Alueista APAC:n odotetaan olevan korkeampi CAGR ennustejakson aikana"

APAC is expected to grow with a high CAGR in the global proteasome inhibitor market in the forecast period. Several factors such as a surge in the development of a wide range of proteasome inhibitors, enhanced accessibility, and diversified healthcare costs are driving the market’s growth during the forecast period. Further, the increase in incidences of pancreatic cancer is also having a positive impact on the market’s growth. For instance, according to the Indian Journal of Medical Sciences in May 2021, in India, pancreatic cancer ranked 24th with 10860 new cases (1.03%). There have been major awareness programs regarding cancer in the region. Thus, APAC is expected to witness a higher CAGR during the forecast period.

Proteasomi-inhibiittorimarkkinat
Proteasomi-inhibiittorimarkkinat

Syyt tämän raportin ostamiseen:

  • Tutkimus sisältää markkinoiden mitoitus- ja ennusteanalyysin, jonka ovat validoineet todennettuja avainalan asiantuntijoita.
  • Raportti esittelee yhdellä silmäyksellä nopean katsauksen alan yleisestä suorituskyvystä.
  • Raportti kattaa syvällisen analyysin merkittävistä alan vertaisryhmistä keskittyen ensisijaisesti tärkeimpiin yritysten taloustietoihin, tuotevalikoimaan, laajentumisstrategioihin ja viimeaikaiseen kehitykseen.
  • Yksityiskohtainen tarkastelu alan kuljettajista, rajoituksista, tärkeimmistä trendeistä ja mahdollisuuksista.
  • Tutkimus kattaa kattavasti markkinat eri segmenteillä.
  • Alan aluetason syvällinen analyysi.

 

Mukautusvaihtoehdot:

The global proteasome inhibitors market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

 

Voit myös ostaa osia tästä raportista. Haluatko tarkistaa osan viisaasti
hinta lista?

Usein kysytyt kysymykset (FAQ)

Q1: What is the current market size and growth potential of the proteasome inhibitor market?

Ans: The proteasome inhibitor market was valued at USD 1.78 Billion in 2022 and is expected to grow at a CAGR of 8.01% during the forecast period (2023-2030).

Q2: What are the driving factors for the growth of the proteasome inhibitor market?

Ans: The surge in awareness programs regarding cancer and rising investments in oncology departments are the driving factors for the growth of the proteasome inhibitor market.

Q3: Which segment has the largest share of the proteasome inhibitor market by mode of administration?

Ans: The oral segment has the largest share of the proteasome inhibitor market by mode of administration.

Q4: What are the emerging technologies and trends in the proteasome inhibitor market?

Ans: Research on finding new target sites on proteasome for developing an effective inhibitor is the emerging technologies and trends in the proteasome inhibitor market.

Q5: Which region will dominate the proteasome inhibitor market?

V: Pohjois-Amerikan odotetaan hallitsevan markkinoita ennustejaksolla.

Q6: Who are the key players operating in the proteasome inhibitor market?

Ans: AbbVie Inc.; Amgen Inc.; Johnson & Johnson Services, Inc.; Takeda Pharmaceutical Company Limited; TG Therapeutics; Pfizer Inc.; QLi5 Therapeutics GmbH; Baxter; GSK plc.; and Kezar Life Sciences Inc. are the key players operating in the proteasome inhibitor market.

1.1.Markkinoiden määritelmät
1.2.Päätavoite
1.3.Sidosryhmät
1.4.rajoitus

 

2.1.Research Process of the Proteasome Inhibitors Market 
2.2.Research Methodology of the Proteasome Inhibitors Market 
2.3.Vastaajan profiili     
3MARKKINASYNOPSIS
4TIIVISTELMÄ
5IMPACT OF COVID-19 ON THE PROTEASOME INHIBITORS MARKET
6PROTEASOME INHIBITORS MARKET REVENUE (USD BN), 2020-2030F
7.1.Oraalinen 
7.2.suonensisäinen
7.3.Muuta 
8.1.Vaippasolulymfooma
8.2.useita myelooma 
8.3.Muuta  
9.1.Pohjois-Amerikka     
 9.1.1.USA   
 9.1.2.Kanada   
 9.1.3.Muu Pohjois-Amerikka 
9.2.Eurooppa     
 9.2.1.Saksa   
 9.2.2.UK   
 9.2.3.Ranska   
 9.2.4.Italia   
 9.2.5.Espanja   
 9.2.6.Muu Eurooppa  
9.3.Aasian ja Tyynenmeren    
 9.3.1.Kiina   
 9.3.2.Japani   
 9.3.3.Intia   
 9.3.4.Muu Aasia-Tyynenmeren alue  
9.4.Muu maailma    
10.1.Markkinoiden kuljettajat
10.2.Markkinahaasteet
10.3.Vaikutusanalyysi
11PROTEASOME INHIBITORS MARKET OPPORTUNITIES
12PROTEASOME INHIBITORS MARKET TRENDS
13.1.Kysyntäpuolen analyysi
13.2.Tarjontapuolen analyysi
14ARVOKETJUANALYYSI
15.1.kilpailutilanteessa 
 15.1.1.Porters Fiverin joukkojen analyysi
16.1.AbbVie Inc.  
16.2.Amgen Inc.  
16.3.Johnson & Johnson Services, Inc.
16.4.Takeda Pharmaceutical Company Limited.
16.5.PKO Therapeutics  
16.6.Pfizer Inc.  
16.7.QLi5 Therapeutics GmbH 
16.8.Baxter   
16.9.GSK plc.   
16.10.Kezar Life Sciences Inc. 
17VASTUUVAPAUSLAUSEKE

Tutkimusmenetelmät

Research Methodology for the Proteasome Inhibitors Market Analysis (2023-2030)

Analyzing the historical market, estimating the current market, and forecasting the future market of the global proteasome inhibitors market were the three major steps undertaken to create and analyze the adoption of proteasome inhibitors in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global proteasome inhibitors market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments of the industry pertains to. Detailed methodology is explained below:

Markkinoiden historiallisen koon analyysi

Vaihe 1: Toissijaisten lähteiden perusteellinen tutkimus:

Detail secondary study was conducted to obtain the historical market size of the proteasome inhibitor market through company internal sources such as vuosikertomukset ja tilinpäätökset, tulosesittelyt, lehdistötiedotteet jne., ja ulkoisista lähteistä mukaan lukien lehdet, uutiset ja artikkelit, hallituksen julkaisut, kilpailijoiden julkaisut, sektoriraportit, kolmannen osapuolen tietokannat ja muut uskottavat julkaisut.

Vaihe 2: Markkinoiden segmentointi:

After obtaining the historical market size of the proteasome inhibitors market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments are included in the report as mode of administration, application, and regions. Further country-level analyses were conducted to evaluate the overall adoption of testing models in that region.

Vaihe 3: tekijäanalyysi:

Hankittuamme eri segmenttien ja alasegmenttien historiallisen markkinakoon, teimme yksityiskohtaisen tekijäanalyysi to estimate the current market size of the proteasome inhibitors market. Further, we conducted factor analysis using dependent and independent variables such as mode of administration, application, and regions of proteasome inhibitors. A thorough analysis was conducted for demand and supply-side scenarios considering top partnerships, mergers and acquisitions, business expansion, and product launches in the proteasome inhibitors market sector across the globe.

Nykyinen markkinakokoarvio ja ennuste

Nykyinen markkinakoko: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the global proteasome inhibitors market, and market shares of the segments. All the required percentage shares split and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.

Arvio ja ennusteet: Markkinoiden arvioinnissa ja ennusteissa painotettiin eri tekijöitä, kuten tekijöitä ja trendejä, rajoituksia ja sidosryhmien käytettävissä olevia mahdollisuuksia. Näiden tekijöiden analysoinnin jälkeen sovellettiin asiaankuuluvia ennustetekniikoita eli ylhäältä alas/alhaalta ylös -lähestymistapaa, jotta saatiin aikaan markkinaennuste vuodelle 2030 00 eri segmenteillä ja alasegmenteillä tärkeimmillä markkinoilla maailmanlaajuisesti. Markkinoiden koon arvioimiseksi käytetty tutkimusmetodologia sisältää:

  • The industry’s market size, in terms of revenue (USD) and the adoption rate of the proteasome inhibitors market across the major markets domestically
  • Kaikki prosenttiosuudet, splitit ja markkinasegmenttien ja alasegmenttien erittelyt
  • Key players in the global proteasome inhibitors market in terms of products offered. Also, the growth strategies adopted by these players to compete in the fast-growing market

 

Markkinoiden koon ja osuuden vahvistaminen

Perustutkimus: Tärkeimmillä alueilla suoritettiin perusteellisia haastatteluja tärkeimpien mielipidejohtajien (KOL) kanssa, mukaan lukien ylimmän tason johtajat (CXO/VP:t, myyntipäällikkö, markkinointipäällikkö, operatiivinen johtaja, aluejohtaja, maajohtaja jne.). Ensisijaiset tutkimustulokset koottiin sitten yhteen ja suoritettiin tilastollinen analyysi esitetyn hypoteesin todistamiseksi. Primääritutkimuksen panokset yhdistettiin toissijaisiin havaintoihin, jolloin tieto muutettiin käyttökelpoisiksi oivalluksiksi.

Ensisijaisten osallistujien jakautuminen eri alueilla

Proteasomi-inhibiittorimarkkinat
Proteasomi-inhibiittorimarkkinat

Markkinasuunnittelu

The data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the global proteasome inhibitor market. Data was split into several segments & sub-segments post studying various parameters and trends in the areas of mode of administration, application, and regions in the global proteasome inhibitors market.

Global Proteasome Inhibitor Market Study -tutkimuksen päätavoite

The current & future market trends of the global proteasome inhibitors market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:

  • Analyze the current and forecast market size of the proteasome inhibitors market in terms of value (USD). Also, analyze the current and forecast market size of different segments and sub-segments
  • Tutkimuksen segmentit sisältävät antotavan, sovelluksen ja alueet
  • Define and analyze the regulatory framework for the proteasome inhibitor industry.
  • Analysoi arvoketjua, joka liittyy erilaisten välittäjien läsnäoloon, sekä analysoi alan asiakkaiden ja kilpailijoiden käyttäytymistä.
  • Analyze the current and forecast market size of the proteasome inhibitors market for the major region.
  • Suurimpia raportissa tutkittuja alueita ovat Aasia ja Tyynenmeren alue, Eurooppa, Pohjois-Amerikka ja muu maailma.
  • Company profiles of the proteasome inhibitors market and the growth strategies adopted by the market players to sustain in the fast-growing market
  • Alan aluetason syvällinen analyysi

 

Voit myös ostaa osia tästä raportista. Haluatko tarkistaa osan viisaasti
hinta lista?